Vactosertib

DB15310InvestigationalSmall molecule

Vactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).

Mechanism: Pharmacologically active on TGF-beta receptor type-1
Curator reviewed
Formula / weight: C₂₂H₁₈FN₇ · 399.433 g/mol (avg)
Code names: TEW-7197

Resolves to

Compound

UNII6T4O391P5YCAS1352608-82-2ChEMBLCHEMBL3260567

Structure

InChIKeyFJCDSQATIJKQKA-UHFFFAOYSA-NSMILESCC1=NC(=CC=C1)C1=C(N=C(CNC2=C(F)C=CC=C2)N1)C1=CN2N=CN=C2C=C1

Targets

P36897TGFBR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

21Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vactosertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account